The Combination of the Proteasome Inhibitor Bortezomib and the Bcl-2 Antisense Molecule Oblimersen Sensitizes Human B-Cell Lymphomas to Cyclophosphamide
Owen A. O’Connor(Virginia Cancer Institute), Asher Chanan‐Khan(WinnMed)
Cited by 46
Related Papers
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|The Lancet Oncology|2010|852
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
|Blood|2011|450
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
|Blood|2017|271
Vitamin C Antagonizes the Cytotoxic Effects of Antineoplastic Drugs
|Cancer Research|2008|222